Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of IBI3004 in advanced solid tumors
CTR20243102Phase 2Terminated
- Sponsor
- InnoCare Pharma
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3004 in Nonhematologic neoplasms, sponsored by InnoCare Pharma. Started Aug 2024; status: terminated.
02
Drugs
IBI3004
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20243102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243102.